ClinicalTrials.gg
Not yet recruitingNCT05590572Updated Oct 21, 2022

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

A Phase 1/2 interventional study of Sulfatinib and Etoposide in Osteosarcoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting at 5 sites in 2 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2022-10-21.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
2 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Osteosarcoma with a site in China — 22 open to participants now, 26 under way, none of them phase 3. Osteosarcoma · China.

Planned enrollment
5th of 42
148 · median 44
Started
2023
with 7 others
Phase 1/2
7 of 60
4 open now
Primary completion
2026-12
later than 21 of 25 live
Registered
30th of 60
by date
Lead sponsor
4 of 60
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 60 studies in Osteosarcoma with a site in China, this one is the 5th largest by planned enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2023, is one of 7 in phase 1/2, reaches primary completion later than 21 of the 25 other live ones, and was the 30th registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

22 of the 60 studies in Osteosarcoma with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Osteosarcoma with a site in China, or all of them as a file.
02

Study summary

This is a phase 1/2 study evaluating safety, tolerability, and efficacy of Sulfatinib in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed osteosarcoma ( combination Sulfatinib).

Read the detailed description

The study consists of 2 cohorts:

Cohort 1 (Traditional chemotherapy) will evaluate the efficacy of ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma.

Cohort 2 (Combination Expansion) will evaluate the efficacy of Sulfatinib in combination with ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma.

Sulfatinib will be provided as hard capsules containing 300 mg Sulfatinib. Sulfatinib capsules should be dissolved in water or apple juice for those who are unable to swallow capsules.

03

Conditions studied

  • Osteosarcoma

Browse trials for

Keywords

  • Refractory or Relapsed osteosarcoma
  • Sulfatinib
  • Tyrosine kinase inhibitors
  • Etoposide
  • Ifosfamide
04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Osteosarcoma subjects Male or female participants aged 2 to 25 years at the time of ( or cytologically confirmed diagnosis of high grade osteosarcoma)
  2. Recurrent or solid tumor that have treated with standard anticancer therapy but have no available treatment options.
  3. Evaluable or that met the following criteria: 1. Participants must have an evaluable or measurable disease based on 1.1, using computed tomography (CT)/ magnetic resonance imaging (MRI). 2. Lesions that have been treated locally, such as external beam radiation therapy (EBRT) or radiofrequency (RF) ablation, must subsequently grow clearly to be considered target lesions.
  4. is 3 months or more.
  5. Adequate bone marrow function : ①. (ANC) ≥ 1.0 x 10\^9/L. ②. ≥ 8.0 g/ deciliter (hemoglobin ≤ 8.0 g/ deciliter is acceptable if corrected by growth factors or transfusion before starting sovanitinib). ③. count ≥ 75 x 10\^9/L.
  6. Adequate liver function: 1. ≤ 1.5 times the (ULN). 2. Alkaline phosphatase, (ALT) and aspartate aminotransferase (AST) ≤3 times of ULN.
  7. Adequate renal function, such as (or radioisotope [GFR]), must be greater than 70 mL/min/ 1.73 square meters.

(8)A baseline (LVEF) of 50% or greater, as determined by echocardiography, indicates adequate cardiac function.

(9) Good control of blood pressure (BP) with or without antihypertensive medication was defined as : blood pressure below 95% for sex, age, and height/length at screening (according to National Heart, Lung, and Blood Institute guidelines) and no change in antihypertensive medication during the cycle 1 of project. participants with osteosarcoma had blood pressure ≤150/90 mm Hg at screening and had no change in antihypertensive therapy during the cycle 1 of project.

(10)Parents or legal representative (guardian) shall sign the written informed consent and obtain the consent of minor participants. Written informed consent from subjects ≥18 years of age. Willing and able to abide by the researchers determine solutions, plans, and toxicity of follow-up management.

Exclusion criteria

Exclusion Criteria:

  1. Any active infection or infectious disease.
  2. Any medical condition or other condition that the investigator believes will prevent the participant from participating in the clinical study.
  3. Other organ toxicity (except hair loss) caused by previous anti-cancer treatment (research drug, chemotherapy or radiotherapy)
  4. Known to any component of the product (soventinib or ingredient).
  5. Any other anti-tumor treatment is given at the same time.
  6. He has been treated with sovantinib before.
  7. Two or more previous VEGF/VEGFR targeted therapies.
  8. Currently receiving any study drug or device in another clinical trial or within 30 days before .
  9. abnormalities, including significant baseline or QTc interval prolongation (e.g., QTc interval duplication is demonstrated to be greater than 480 milliseconds).
  10. Gastrointestinal malabsorption or any other condition that the investigator believes may affect the absorption of sovantinib.
  11. Gastrointestinal bleeding or active hemoptysis (at least half a teaspoon of bright red blood) occurred within 3 weeks before the first administration of the study drug.
  12. Active second malignant tumor (excluding superficial melanoma, in situ, basal or squamous cell skin cancer with definite treatment) within 2 years before enrollment.
  13. Previously treated with ifosfamide with nephrotoxicity or encephalopathy grade greater than or equal to grade 3.

Women who were breastfeeding or pregnant at the time of screening or baseline. If a negative screening pregnancy test is obtained more than 72 hours before the first administration of the study drug, a separate baseline assessment is required.

-

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
148 participants (estimated)

Study arms

  • Active comparator
    Etoposide plus Ifosfamide group

    Children and adolescents with relapsed or refractory drug resistant osteosarcoma

    Drug: Etoposide · Drug: Isophosphamide

  • Experimental
    Etoposide plus Ifosfamide Combined With Sulfatinib

    Children and adolescents with relapsed or refractory drug resistant osteosarcoma

    Drug: Sulfatinib · Drug: Etoposide · Drug: Isophosphamide

Interventions

  • DrugSurufatinibStudies of SurufatinibSurufatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    (1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle

  • (1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;

  • DrugIfosfamideStudies of IfosfamideIfosfamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    (1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.

06

What researchers measure

Primary outcomes

  1. 4 months progression-free survival

    The proportion of patients who had no objective tumor progression or death from the start of treatment to 4 months of follow-up.

    Time frame: 4 months

  2. Efficacy evaluation in solid tumors

    Complete response (CR), all target and non-target lesions (non-lymph nodes) disappear, and the diameter of all pathologic lymph nodes (both target and non-target) must be reduced to \<10 mm; Partial response (PR), using baseline total diameter as reference, reduced the total diameter of target lesions by at least 30%.

    Time frame: 2 months

Secondary outcomes

  1. Best of response,BOR

    From the date of the first administration of the study drug to disease progression or death, whichever occurs first.

    Time frame: 4 months

  2. Duration of Remission (DOR)

    Complete response (CR)/ partial response (PR) was first recorded until disease progression was first recorded until the data cutoff date.

    Time frame: 2 years

07

Study locations

5 sites
  • Peking University People's Hospital
    Beijing, Beijing 100000, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
    • Zhenfeng Li, PhD · Contact13668812855
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200000, China
  • Department of Orthopaedic Surgery, Sixth People's Hospital, Shanghai Jiao Tong University,
    Shanghai, Shanghai 200233, China
  • Department of Orthopedic Surgery Chonnam National University
    Donggu, Gwangju 999007, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2023; primary completion for Dec 2026, 47 months later.

Of 33 phase 1/2 interventional studies under Osteosarcoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 92. This study's planned 47 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2022
First posted
Oct 21, 2022
StartEst.
Jan 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Oct 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05590572
Collaborators
Chonnam National University, Peking University People's Hospital, Qilu Hospital of Shandong University, Ruijin Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Jan 2023 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 21, 2022

Study contacts

Zhaoming Ye, PhD
Contact
yezhaoming@zju.edu.cn
13606501549
zengjie zhang, MD
Contact
zengjiezhang@zju.edu.cn
19858877686
zhaoming Ye, PhD
study chair · Second Affiliated Hospital, School of Medicine, Zhejiang University
Binhao Li, PhD
study director · Second Affiliated Hospital, School of Medicine, Zhejiang University
zengjie zhang, MD
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University
Shengdong Wang, MD
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University
Xin Huang, PhD
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University
Peng Lin, MD
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Surufatinib

Start the discussion